These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

883 related items for PubMed ID: 11606380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 3,3'4,4'-Tetrachlorobiphenyl exhibits antiestrogenic and antitumorigenic activity in the rodent uterus and mammary cells and in human breast cancer cells.
    Ramamoorthy K, Gupta MS, Sun G, McDougal A, Safe SH.
    Carcinogenesis; 1999 Jan; 20(1):115-23. PubMed ID: 9934858
    [Abstract] [Full Text] [Related]

  • 3. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells.
    Bhat KP, Pezzuto JM.
    Cancer Res; 2001 Aug 15; 61(16):6137-44. PubMed ID: 11507064
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis.
    Kisková T, Ekmekcioglu C, Garajová M, Orendáš P, Bojková B, Bobrov N, Jäger W, Kassayová M, Thalhammer T.
    Eur J Cancer Prev; 2012 Mar 15; 21(2):163-70. PubMed ID: 22044852
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.
    Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM.
    Endocrinology; 2000 Oct 15; 141(10):3657-67. PubMed ID: 11014220
    [Abstract] [Full Text] [Related]

  • 15. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
    Swanson SM, Christov K.
    Anticancer Res; 2003 Oct 15; 23(4):3207-13. PubMed ID: 12931682
    [Abstract] [Full Text] [Related]

  • 16. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
    Lee O, Choi MR, Christov K, Ivancic D, Khan SA.
    Cancer Lett; 2016 Jul 01; 376(2):310-7. PubMed ID: 27080304
    [Abstract] [Full Text] [Related]

  • 17. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.
    Mehta RG, Williamson E, Patel MK, Koeffler HP.
    J Natl Cancer Inst; 2000 Mar 01; 92(5):418-23. PubMed ID: 10699072
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2002 Jun 01; 8(6):1995-2001. PubMed ID: 12060645
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.